Fig. 2: Effects of the D2/D3 antagonist amisulpride on human-motivated behaviour, hedonic and emotional responses, motor function and reward processing.
From: Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
A Effect of amisulpride vs placebo on negative symptoms (Brief Negative Symptom Scale, individual values with mean ± SE). n = 29, linear mixed-effects model: b = 4.62, t(49) = 2.51, 95% CI = 0.92:8.32, two-sided p = 0.015. B Effect of amisulpride vs placebo on akathisia (Barnes Akathisia Rating Scale, individual values with mean ± SE). n = 29, linear mixed effects model: b = 1.48, t(50) = 4.53, 95% CI = 0.83:2.14, two-sided p = 3.63 × 10−5. C Effect of amisulpride vs placebo on parkinsonism (Simpson Angus Scale, individual values with mean ± SE). n = 29, linear mixed effects model: b = 1.03, t(50) = 3.12, 95% CI = 0.37:1.69, two-sided p = 0.0030. D Effect of amisulpride vs placebo on caudate activation during reward outcome in monetary incentive delay (MID) task (individual values with mean ± SE of beta values). n = 21, paired sample t-test: mean difference = −146.2, t(20) = 3.17, 95% CI = −50.0:−242.4, FDR corrected two-sided p = 0.014. E Relationship between change in caudate BOLD signal during reward outcome on amisulpride and plasma amisulpride levels (μg/L). n = 22, Pearson’s r = −0.44, FDR corrected p-value = 0.041. F Relationship between reduction in caudate reward outcome activation and ranked increase in negative symptoms on amisulpride (BNSS). n = 21, Spearman’s rho = −0.49, FDR corrected p-value = 0.041. G Whole-brain statistical maps showing areas of reduced BOLD signal on amisulpride vs placebo during reward outcome. n = 21. Colour bar indicates z-statistic. Source data are provided as a Source data file.
